In this study, we provided a clear and comprehensive preclinical evaluation of a FAK inhibitor, TAE226, studied in HCC cells in order to explore its potential use as first-line therapy in combination with SOR. The gene discussed is PTK2; the disease is hepatocellular carcinoma.